ReGEN Biomedical
ReGEN Biomedical develops advanced micro-tissue products and automated manufacturing technologies that help accelerate regenerative medicine from research to real-world application. Their high-quality micro-tissues enable more predictive drug screening, toxicity testing and disease modelling, while our expertise in automation and process development helps organizations scale production in a reliable and reproducible way.
As a Contract Research Organization (CRO), ReGEN Biomedical supports academic groups, biotech companies and industry partners with, process optimization, automation and manufacturing solutions for organoids, spheroids, microtissues or Regenerative Medicine solutions.
Working at the intersection of biology, engineering and manufacturing, ReGEN helps bridge the gap between scientific innovation and scalable production. ReGEN Biomedical collaborates closely with partners across the regenerative medicine ecosystem, including Maastricht University, MUMC+, MERLN Institute, RegMed XB and a growing network of academic, clinical and industrial partners. The company is supported by public and private investments, including funding through the Dutch National Growth Fund programme RegMed XB.
